Can oral sirolimus therapy prevent in-stent restenosis?
Schiele
Thomas M
TM
Interventional Cardiology Division, University Hospital of the Ludwig-Maximilians-University München Innenstadt, Munich, Germany. Thomas.Schiele@med.uni-muenchen.de
D000284:Administration, Oral; D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000601:surgery; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D011475:Prosthesis Failure; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus